Quadrivalent Flu Vaccine for NIP, failed in bidding

It failed in bidding three times earlier. fourth attempt on the 13th

The government is sticking to the ₩8,000 range

The government's supply contract in October may be disrupted.

The procurement of a tetravalent vaccine for influenza for NIP failed bidding three times due to an excessively low unit price.

 

According to related industries on the 10th, two bids for the '2020-2021 season influenza vaccine purchase' conducted by the KCDC were failed on the 28th of last month.

 

Initially, New Medipharm and PharmWorld (NIP, local government project, AI response, etc.) and Seojun Pharm (children, pregnant women) were each successful bidder, but both failed to submit a supply confirmation and gave up delivery.

 

The government's low unit price setting is blamed as the reason for abandoning delivery.

 

The government set the estimated unit price for a quadrivalent flu vaccine at ₩8,790.

 

This is only 60% of the usual supply price of ₩14,000 to ₩15,000 for tetravalent vaccines.

 

Even this is also somewhat increased due to the failure in bidding.

 

At the time of the first bidding on the 2nd of last month, the estimated unit price suggested by the KCDC is ₩8,490.

 

Wholesalers who did not receive a supply agreement from the manufacturer at an excessively low price eventually gave up supply.

 

Accordingly, the government slightly increased the unit price to ₩8,610, but it was sold as a single bid.

 

In the third bid, ₩8,790 was offered, but the final successful bid was not achieved.

 

It is in danger of delaying the government's plan to complete the contract in July and begin purchasing in August with subsequent reservations to begin full-fledged vaccination from October.

 

The government plans to conduct an urgent bid to purchase an influenza vaccine on the 13th, but the possibility of failing in bidding remains as it is applying the same unit price as the last bid.

 

An official from the flu vaccine manufacturing industry said, "The government’s proposed tetravalent vaccine supply price is almost no difference compared to the trivalent vaccine price, which has a low production cost." Also, as the NIP supply price decreases, the difference between the supply price in the private market widens, which is a burden for manufacturers.

 

This is because the greater the gap, the stronger the demand for price cuts in the private market will increase.